These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17354608)

  • 1. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals.
    Prasanphanich AF; Lane SR; Figueroa SD; Ma L; Rold TL; Sieckman GL; Hoffman TJ; McCrate JM; Smith CJ
    In Vivo; 2007; 21(1):1-16. PubMed ID: 17354608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies.
    Kunstler JU; Veerendra B; Figueroa SD; Sieckman GL; Rold TL; Hoffman TJ; Smith CJ; Pietzsch HJ
    Bioconjug Chem; 2007; 18(5):1651-61. PubMed ID: 17663527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Kannan R; Volkert WA; Hoffman TJ
    Cancer Res; 2003 Jul; 63(14):4082-8. PubMed ID: 12874010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
    Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
    Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor.
    Lane SR; Veerendra B; Rold TL; Sieckman GL; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2008 Apr; 35(3):263-72. PubMed ID: 18355681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bombesin analogues for gastrin-releasing peptide receptor imaging.
    Nanda PK; Pandey U; Bottenus BN; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Smith CJ
    Nucl Med Biol; 2012 May; 39(4):461-71. PubMed ID: 22261143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
    García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
    Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the (99m)Tc(CO)3(+) core.
    Bouziotis P; Gourni E; Patsis G; Psimadas D; Zikos C; Fani M; Xanthopoulos S; Loudos G; Paravatou-Petsotas M; Livaniou E; Varvarigou AD; Pirmettis I; Papadopoulos M
    Bioorg Med Chem; 2013 Nov; 21(21):6699-707. PubMed ID: 24035515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
    Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
    Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [(99m)Tc]Demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models.
    Nock BA; Cescato R; Ketani E; Waser B; Reubi JC; Maina T
    J Med Chem; 2012 Oct; 55(19):8364-74. PubMed ID: 22966957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
    Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
    Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties.
    Smith CJ; Gali H; Sieckman GL; Higginbotham C; Volkert WA; Hoffman TJ
    Bioconjug Chem; 2003; 14(1):93-102. PubMed ID: 12526698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
    Jackson AB; Nanda PK; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Chen X; Smith CJ
    Nucl Med Biol; 2012 Apr; 39(3):377-87. PubMed ID: 22226021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
    Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.